Friday, July 10, 2026

pharma · cystic fibrosis · Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)

Théa Pharma Ireland

Verona Pharma Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include cystic fibrosis, Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive), multifocal spasticit

Castlebar, IE HQ
2018 Founded
19 Employees
EMA registrant Type
Company details
Status
Public
HQ
Castlebar, IE
Founded
2018
Employees
19
Programs
11
Drugs
42
Patents
0
Clinical program

DISCARD

Approved · small molecule · Patients with currently remitted depressive disorders.

DISCARD for Patients with currently remitted depressive disorders. is a Approved program (small_molecule) at Verona Pharma Ireland Limited with 1 ClinicalTrials.gov record(s).

Internal code DISCARD

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Verona Pharma Ireland Limited
Phase
Approved
Modality
small_molecule
Indication
Patients with currently remitted depressive disorders.
Status
active
Trials
1